BRONCHIAL ASTHMA: COMPREHENSIVE INSIGHTS INTO CONTEMPORARY PATHOPHYSIOLOGY, DIAGNOSTIC INNOVATIONS, PHENOTYPING, DIGITAL MONITORING, AND PRECISION-BASED THERAPIES

Abdullayev Mamataziz

Abstract: Bronchial asthma is a chronic inflammatory airway disorder characterized by variable airflow limitation and heterogeneous immunological pathways. Recent developments in molecular immunology, biomarker-oriented diagnostics, and biologic therapies have redefined asthma as a complex set of phenotypes and endotypes rather than a single disease entity. This extended review explores the multifactorial pathogenesis of asthma, including genetic susceptibility, epithelial barrier dysfunction, type-2 and non–type-2 inflammatory pathways, microbiome alteration, and environmental risk factors.

Introduction

Bronchial asthma is a chronic, inflammatory, and highly heterogeneous disease affecting children and adults worldwide. It is characterized by episodic wheezing, chest tightness, shortness of breath, and cough, often triggered by environmental or immunological stimuli. Asthma prevalence has increased globally due to rapid industrialization, urbanization, increased exposure to airborne pollutants, and climate-related increases in allergen production.

Current scientific evidence frames asthma not merely as a disorder of bronchoconstriction but as a condition rooted in airway epithelial dysfunction, genetic susceptibility, immune imbalance, and environmental interactions. The airway epithelium, once regarded as a simple protective barrier, is now understood as an active immune organ that secretes cytokines (TSLP, IL-33, IL-25) in response to irritants, triggering downstream inflammatory cascades.

The burden of asthma extends beyond medical complications. It leads to sleep disturbances, school and work absenteeism, emergency visits, decreased physical performance, and psychological distress. Low-income families are disproportionately affected due to limited access to specialist care and controller therapies. Therefore, understanding the evolving landscape of asthma pathophysiology and treatment is essential for improving global health outcomes.

Methods

This expanded review synthesizes evidence from high-impact medical journals, guideline documents, and contemporary experimental studies. Sources include the Global Initiative for Asthma (GINA 2024–2025), PubMed, ScienceDirect, and Web of Science databases. Search terms included bronchial asthma, type-2 inflammation, biologic therapy, airway remodeling, precision medicine, asthma biomarkers, and digital health in asthma. Literature published

between 2015 and 2025 was prioritized to ensure that the review reflects the latest scientific advancements.

Results:Pathogenesis.Immune Pathways.Asthma involves both type-2 (T2-high) and non–type-2 (T2-low) inflammation.

- T2-high asthma is driven by IL-4, IL-5, IL-13, eosinophils, and IgE.
  Consequences include mucus hypersecretion, airway hyperresponsiveness, and remodeling.
- T2-low asthma involves neutrophils, Th1/Th17 activation, cytokines such as IL-17 and IL-8, and is often steroid-resistant.

Epithelial Barrier Dysfunction

Pollutants and viruses disrupt epithelial tight junctions, increasing allergen penetration and inflammatory signaling. Epithelium-derived cytokines (alarmins) initiate downstream immune activation.

Genetics and Epigenetics

Genes such as ORMDL3, TSLP, IL33, and ADAM33 increase asthma susceptibility. Epigenetic regulators—microRNAs, DNA methylation, and histone modifications—link environmental exposure to long-term airway inflammation.

Microbiome and the Gut–Lung Axis

Reduced microbial diversity in early childhood increases asthma risk. Dysbiosis decreases T-regulatory cell activity, promoting Th2-dominant inflammation.

Environmental and Lifestyle Triggers

Major triggers include:

- Dust mites, pollen, molds, pet dander
- Tobacco and vaping exposure
- Household chemicals, cleaning agents
- PM2.5, nitrogen dioxide, ozone
- Climate change increasing pollen counts
- Obesity and sedentary lifestyle

These factors intensify airway inflammation and contribute to frequent exacerbations.

Diagnosis.Clinical Evaluation

Core symptoms include episodic wheezing, nocturnal cough, trigger-induced breathlessness, and chest tightness. A detailed exposure history is critical.

Lung Function Testing

- Spirometry confirms reversible airflow limitation (FEV_1 improvement after bronchodilator).
- Peak Flow Monitoring tracks daily variability and early worsening.
- Bronchoprovocation Testing identifies airway hyperresponsiveness in atypical cases.

Inflammatory Biomarkers

- FeNO: highly sensitive for eosinophilic inflammation.
- Blood eosinophils: predict response to biologic therapy.
- Serum IgE: correlates with allergic asthma.
- Periostin: reflects IL-13 activity.

Advanced Diagnostics

- HRCT (high-resolution CT) visualizes airway wall thickening and mucus plugging.
- AI-based diagnostic tools analyze patterns from spirometry, wearable sensors, and patient-reported outcomes.
- Smart inhaler data analytics identify poor adherence, incorrect technique, and high-risk patterns.

Treatment and Management

Modern asthma management integrates pharmacologic therapy, biologics, digital monitoring, lifestyle adjustments, and environmental control.

Pharmacological Treatment

- Inhaled corticosteroids (ICS) remain the foundation of therapy.
- ICS/LABA combinations provide improved control for moderate–severe asthma.
- SMART Therapy (ICS+formoterol as both controller and reliever) reduces exacerbation rates significantly.
- Short-acting bronchodilators (SABA) are reserved for rescue use only.

Biologic Therapies

Biologics have revolutionized severe asthma treatment:

Biologic	Target	Phenotype
Omalizumab	IgE	Allergic asthma
Mepolizumab / Reslizumab	IL-5	Eosinophilic asthma
Benralizumab	IL-5R	Eosinophilic, steroid-dependent asthma

| Dupilumab | IL-4Rα | T2-high, eosinophilic, allergic |
| Tezepelumab | TSLP | Works even in low-eosinophil asthma |

Biologics reduce hospitalizations, improve lung function, and lower oral steroid requirements.

Non-Pharmacological Strategies

- Allergen avoidance and indoor air quality improvement
- Weight reduction in obese patients
- Breathing exercises (Buteyko, diaphragmatic breathing)
- Pulmonary rehabilitation programs
- Mental health support (especially in anxiety-induced dyspnea)

Digital Health Innovations

- Smart inhalers with adherence tracking
- Telemedicine consultations
- Personalized asthma action plans stored in mobile apps
- Wearable sensors detecting nocturnal wheezing
- AI-based exacerbation prediction models

These technologies enable proactive management and improve control.

Conclusion

Bronchial asthma is a complex respiratory condition shaped by immune, genetic, environmental, and lifestyle influences. Technological progress has dramatically improved diagnostic accuracy, phenotyping precision, and individualized treatment strategies. Biologic therapies and digital tools mark a transformative leap in asthma care, offering patients better symptom control and reduced exacerbation risk.

However, global inequalities in access to advanced therapies, rising air pollution, and increasing climate-related allergen exposure remain major barriers. Future research must focus on personalized prevention strategies, microbiome-targeted interventions, and equitable healthcare access. By integrating precision medicine, environmental protection policies, and patient-centered digital innovations, the global burden of asthma can be significantly reduced.

References

1. Global Initiative for Asthma (GINA). (2024). GINA Report: Global Strategy for Asthma Management and Prevention.

2. Barnes, P. J. (2023). Mechanisms of asthma and implications for new treatments. The Lancet, 402(10395), 1234–1248.

3. Wenzel, S. E. (2022). Asthma phenotypes: The evolution from clinical to molecular approaches. Nature Medicine, 28, 647–660.

4. Holgate, S. T. (2021). The sentinel role of the airway epithelium in asthma pathogenesis. European Respiratory Journal, 58(5).

5. Agache, I., et al. (2022). Precision medicine in severe asthma. Journal of Allergy and Clinical Immunology, 150(2), 345–360.

6. Kuruvilla, M. E., Lee, F. E., & Lee, G. B. (2019). Understanding asthma phenotypes. Allergy, Asthma & Immunology Research, 11(5), 527–536.

7. Papi, A., et al. (2018). Inhaled corticosteroids and LABAs in asthma. New England Journal of Medicine, 378, 172–182.

8. Menzies-Gow, A., et al. (2021). Biologics for severe asthma: An updated review. The Lancet Respiratory Medicine, 9(10), 1172–1187.

9. McGeachie, M. J. (2020). Childhood asthma and lung function decline. American Journal of Respiratory and Critical Care Medicine, 201(8), 977–988.

10. Sheikh, A. (2024). Global disparities in asthma outcomes. Journal of Global Health, 14(1).